JP Morgan Upgrades Recursion Pharmaceuticals to Overweight, Raises Price Target to $11

Benzinga · 2d ago
JP Morgan analyst Eric Joseph upgrades Recursion Pharmaceuticals (NASDAQ:RXRX) from Neutral to Overweight and raises the price target from $10 to $11.